Heron Therapeutics, Inc. (HRTX) P/B ratio

P/B ratio today
3.3×

Heron Therapeutics, Inc. (HRTX) trades at 3.3× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 15.1×. Today's figure is 78.3% below the fiscal 2025 year-end. Figures as of 18 Nov 2026, 12:49 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/B ratio today
3.3×
P/B ratio, fiscal 2025
15.1×
Highest on record
20.1×fiscal 2022
Lowest on record
11.6×fiscal 2021
Fiscal years on record
32021–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Heron Therapeutics, Inc. P/B ratio, in more detail

Across the 3 fiscal year-ends on record (2021–2025), the highest was 20.1× in fiscal 2022 and the lowest 11.6× in fiscal 2021. Today's P/B ratio is at or below every one of the 3 fiscal year-ends on record; their median is 15.1×.

History · 3 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Heron Therapeutics, Inc. P/B ratio, year by year

Heron Therapeutics, Inc. (HRTX) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today3.3×—$0.28—
202515.1×—$1.30$0.09
2024——$1.53-$0.22
2023——$1.70-$0.25
202220.1× 73.1% up$2.50$0.12
202111.6×—$9.13$0.79
2020——$21.17—
2019——$23.50—
2018——$25.94—
2017——$18.10—
2016——$13.10—
2015——$26.70—
2014——$10.06—
2013——$9.00—
2012——$11.00—
2011——$4.60—
2010——$9.00—
2009——$25.20—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

More on HRTX

Heron Therapeutics, Inc., figure by figure

Heron Therapeutics, Inc. (HRTX) overview: price, valuation and scorecard

Heron Therapeutics, Inc. P/B ratio: questions and answers

What is Heron Therapeutics, Inc.'s P/B ratio?

Heron Therapeutics, Inc. (HRTX) trades at 3.3× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 15.1×.

Is Heron Therapeutics, Inc.'s P/B ratio high or low compared with its own history?

Today's P/B ratio is at or below every one of the 3 fiscal year-ends on record; their median is 15.1×.

What are the highest and lowest P/B ratio figures on record for Heron Therapeutics, Inc.?

Across the 3 fiscal year-ends on record (2021–2025), the highest was 20.1× in fiscal 2022 and the lowest 11.6× in fiscal 2021.

How is Heron Therapeutics, Inc.'s P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Heron Therapeutics, Inc. it is on record here for 3 fiscal years, 2021 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Heron Therapeutics, Inc. (HRTX) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/HRTX/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.